Kymera Therapeutics (KYMR) Cash from Operations (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Cash from Operations data on file, last reported at 88840000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations fell 12.24% year-over-year to 88840000.0 in Q1 2026; TTM through Mar 2026 was 242581000.0, a 3.64% decrease from a year earlier, with the FY2025 full-year figure at 232891000.0, down 19.74% from the prior year.
• Cash from Operations for Q1 2026 stood at 88840000.0, down from 66747000.0 in the prior quarter.
• Over the last five years, Cash from Operations for KYMR reached as high as 8045000.0 in Q4 2023 and fell as low as 88840000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 45420176.47 across 5 years, with a median of 40295000.0 in 2022.
• Across the five-year window, Cash from Operations surged 120.35% in 2023 and sank 867.98% in 2024, its largest moves.
• Year by year, Cash from Operations stood at 39536000.0 in 2022, then jumped by 120.35% to 8045000.0 in 2023, then sank by 867.98% to 61784000.0 in 2024, then fell by 8.03% to 66747000.0 in 2025, then tumbled by 33.1% to 88840000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 88840000.0 in Q1 2026, 66747000.0 in Q4 2025, and 27110000.0 in Q3 2025.